Polo-like kinase 1 promotes sepsis-induced myocardial dysfunction

Zhenqiang Gao,Cuiting Zheng,Yaqi Xing,Xiyu Zhang,Yunfei Bai,Chen Chen,Yuanyuan Zheng,Wen Wang,Hongbing Zhang,Yan Meng
DOI: https://doi.org/10.1016/j.intimp.2023.111074
IF: 5.714
2023-10-24
International Immunopharmacology
Abstract:Sepsis-induced myocardial dysfunction (SIMD) is the main cause of mortality in sepsis. In this study, we identified Polo-like kinase 1 (Plk-1) is a promoter of SIMD. Plk-1 expression was increased in lipopolysaccharide (LPS)-treated mouse hearts and neonatal rat cardiomyocytes (NRCMs). Inhibition of Plk-1 either by heterozygous deletion of Plk-1 or Plk-1 inhibitor BI 6727 alleviated LPS-induced myocardial injury, inflammation, cardiac dysfunction, and thereby improved the survival of LPS-treated mice. Plk-1 was identified as a kinase of inhibitor of kappa B kinase alpha (IKKα). Plk-1 inhibition impeded NF-κB signal pathway activation in LPS-treated mouse hearts and NRCMs. Augmented Plk-1 is thus essential for the development of SIMD and is a druggable target for SIMD.
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?